Field Notes: HF Final, Destruction Gap, Vendor Squeeze
A finalized guidance with a records trap, two recalls that ask the same question, and a QMS vendor that just doubled its price.
1. FDA Finalized the Human Factors Guidance. The Trap Is the Comparative URRA.
FDA published the final Content of Human Factors Information in Medical Device Marketing Submissions on May 29, closing a 3.5-year pipeline from the December 2022 draft. The framework pivots on a single concept, the “critical task,” and routes every submission into one of three Categories. Operative readiness date: August 1, 2026.
The trap most manufacturers will hit isn’t the new 9-column URRA table required in Category 3. It’s the comparative URRA expectation for modified devices. The guidance requires explicit analysis of tasks upstream and downstream of the change, not only the directly changed tasks. A modification that introduces no new critical task can still impact an existing critical task. That’s enough to leave Category 1, where most modified-device pipelines quietly assume they live.
The QMSR records hook is the second-order story. The guidance is explicit: manufacturers must keep HF records “to the extent required under applicable law, including the Quality Management System Regulation.” Translation: HF evidence belongs in the DHF or DDF under 21 CFR § 820.30 design controls, not in a regulatory-submissions folder. If your HF evidence lives in a submissions repository rather than a design-control file, you have a records-architecture problem the new guidance just made expensive. 64 days to readiness.
Source: FDA, Content of Human Factors Information in Medical Device Marketing Submissions, May 29, 2026. Federal Register 2026-10734.
2. Two Diabetes-Care Actions, Same Day. Two Different Clauses. One Audit Question.
May 26 delivered two field actions in the same therapeutic vertical within hours of each other. Dexcom disclosed that G7 sensors marked for destruction were diverted during disposal and resold to end customers through an unauthorized distributor. The same day, Insulet expanded a correction, originally issued March 12 for the Omnipod 5, to roughly 7 million Omnipod 5, DASH, and Eros pods for insulin under-delivery, traced to a tear in the cannula tubing above the skin. Same vertical, same day, two different ISO 13485:2016 clauses.
The Dexcom event is a § 8.3.3 problem: control of nonconforming product. Most QMS programs treat scrap destruction as a logistics task documented by a manifest. A manifest of intent to destroy is not evidence of destruction. Scrap that re-enters the market is the textbook sign that the disposition record stopped at the originating site and never closed at the destruction site.
The Insulet event is a § 7.5.6 problem, but the sharper question is containment. The March correction addressed one tear, one process. The May action is a different tear, a different process, and roughly 7 million pods. That scope tells you the initial risk impact analysis drew the boundary too tight: containment scoped to the March failure mode never reached the adjacent one already sitting in distribution.
The operator-grade question both events surface: Show me destruction evidence, not destruction-intent records. Show me how containment was scoped against the initial impact analysis, not the closure memo. Both clauses sit in the post-QMSR top-five cited list.
Sources: Dexcom theft disclosure, FDA, May 26, 2026. MDDI, May 26, 2026. FDA recall record, Insulet Omnipod correction expanded May 26, 2026. Insulet Form 8-K, May 26, 2026. MedTech Dive, May 26, 2026.
3. The QMS Vendor Floor Just Moved. Watch the Mid-Market Migrate.
OpenRegulatory reported in December 2025 that Greenlight Guru customers were being told to expect a roughly 100% price increase starting January 2026, framed internally as a “package separation.” Verified contract data now confirms it: mid-market manufacturers with multiple modules are landing quotes of $50K to $60K+ annually where they were previously in the $25K to $35K range. Multi-year lock-in is standard. The Greenlight blog has been silent since April 28. Five weeks of nothing is not a content gap. It’s a posture.
When an incumbent QMS vendor doubles mid-market pricing while AI-native entrants unbundle quality into thin agents, that’s a value-capture decision, not a product-investment one. Manufacturers who got repriced out of their existing tier aren’t going back to paper or to homegrown SharePoint binders. They’re going to evaluate the next tier of platforms over the next two quarters, and they’ll be more open to the conversation than they were a year ago.
For QA/RA leaders carrying a Greenlight renewal in Q3 or Q4: run the parallel evaluation now, not in the renewal quarter. For investors holding the QMS-software thesis: the category leader just told the market it’s optimizing for ARR per logo, not logo count. That’s the moment newer platforms get their swing.
Sources: OpenRegulatory, December 2025. CheckThat.ai Greenlight Guru pricing breakdown, May 2026.